Glucose promotes bacterial growth. Sodium-glucose transporter 2 inhibition (SGLT2i), which prevents glucose recovery from the urine, is standard therapy in chronic kidney diseases. However, kidney bacterial infection rates did not increase. Here, we investigated possible underlying mechanisms contributing to this effect.
Glucose promotes bacterial growth. Sodium-glucose transporter 2 inhibition (SGLT2i), which prevents glucose recovery from the urine, is standard therapy in chronic kidney diseases. However, kidney bacterial infection rates did not increase. Here, we investigated possible underlying mechanisms contributing to this effect.